SVWAG
VRTX icon

Sound View Wealth Advisors Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Sound View Wealth Advisors Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
4,169
+306
+8% +$136K 0.13% 135
2026
Q1 		$1.72M Sell
3,863
-7
-0.2% -$3.26K 0.12% 137
2025
Q4 		$1.75M Buy
3,870
+241
+7% +$104K 0.12% 135
2025
Q3 		$1.42M Buy
3,629
+5
+0.1% +$2.09K 0.1% 159
2025
Q2 		$1.61M Buy
3,624
+94
+3% +$43.3K 0.12% 141
2025
Q1 		$1.71M Buy
3,530
+94
+3% +$43.8K 0.14% 130
2024
Q4 		$1.38M Buy
3,436
+136
+4% +$63K 0.11% 153
2024
Q3 		$1.53M Buy
3,300
+320
+11% +$154K 0.13% 143
2024
Q2 		$1.4M Sell
2,980
-51
-2% -$22.1K 0.14% 133
2024
Q1 		$1.27M Sell
3,031
-182
-6% -$76.9K 0.14% 146
2023
Q4 		$1.31M Sell
3,213
-74
-2% -$27.3K 0.14% 138
2023
Q3 		$1.14M Buy
3,287
+226
+7% +$79K 0.14% 134
2023
Q2 		$1.08M Sell
3,061
-263
-8% -$88.6K 0.14% 138
2023
Q1 		$1.05M Buy
3,324
+111
+3% +$33.3K 0.14% 135
2022
Q4 		$1.31M Buy
3,213
+931
+41% +$284K 0.14% 138
2022
Q3 		$661K Buy
2,282
+38
+2% +$10.9K 0.15% 132
2022
Q2 		$632K Sell
2,244
-757
-25% -$203K 0.13% 144
2022
Q1 		$783K Sell
3,001
-49
-2% -$11.6K 0.15% 131
2021
Q4 		$670K Buy
3,050
+194
+7% +$37.7K 0.13% 148
2021
Q3 		$518K Buy
2,856
+454
+19% +$88.6K 0.11% 164
2021
Q2 		$484K Buy
2,402
+1,096
+84% +$229K 0.1% 179
2021
Q1 		$281K Buy
1,306
+160
+14% +$35.1K 0.07% 229
2020
Q4 		$271K Buy
1,146
+134
+13% +$30.7K 0.07% 215
2020
Q3 		$275K Buy
1,012
+11
+1% +$3.04K 0.07% 202
2020
Q2 		$291K Buy
1,001
+94
+10% +$25.5K 0.08% 192
2020
Q1 		$216K Buy
+907
New +$208K 0.07% 200

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sound View Wealth Advisors Group's VRTX Position: Q2 2026 in Review

Sound View Wealth Advisors Group increased its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q2 2026, buying an estimated $136K and bringing the position to 4,169 shares worth $2.07M. The position accounts for 0.13% of the portfolio, ranked #135.

Sound View Wealth Advisors Group first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sound View Wealth Advisors Group held 4,169 shares of Vertex Pharmaceuticals worth $2.07M as of Q2 2026.
  • Sound View Wealth Advisors Group bought 306 Vertex Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Vertex Pharmaceuticals made up 0.13% of Sound View Wealth Advisors Group's portfolio in Q2 2026, its #135 holding.
  • Sound View Wealth Advisors Group first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sound View Wealth Advisors Group's 13F filing for Q2 2026, filed 11 Aug 2026.